tetano
Editor, Senior Moderator
J Mol Cell Biol
. 2020 Dec 30;mjaa071.
doi: 10.1093/jmcb/mjaa071. Online ahead of print.
SARS-CoV-2 infection and the antiviral innate immune response
Hui Yang[SUP] 1 2 [/SUP], Yingying Lyu[SUP] 1 2 [/SUP], Fajian Hou[SUP] 3 4 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in December 2019, causing the illness known as the novel coronavirus disease 2019 (COVID-19). The virus spread rapidly worldwide to become a global public health emergency. As of 15 November 2020, more than 53 million confirmed cases and over one million deaths worldwide have been reported (World Health Organization, 2020). The SARS-CoV-2 genome was sequenced and studies are ongoing to further understand the epidemiology, clinical manifestations, etiological structure, cellular receptor angiotensin II converting enzyme (ACE2), and intracellular replication process of the virus. Currently, thousands of clinical trials related to SARS-CoV-2 are underway (https://clinicaltrials.gov/). However, no vaccines or drugs have yet been approved, until very recently, for direct treatment or prevention of COVID-19 and only supportive treatment has been applied clinically. This review will discuss the possible mechanism of the innate immune response to SARS-CoV-2 infection and provide insight into the development of related therapeutics.
. 2020 Dec 30;mjaa071.
doi: 10.1093/jmcb/mjaa071. Online ahead of print.
SARS-CoV-2 infection and the antiviral innate immune response
Hui Yang[SUP] 1 2 [/SUP], Yingying Lyu[SUP] 1 2 [/SUP], Fajian Hou[SUP] 3 4 [/SUP]
Affiliations
- PMID: 33377937
- DOI: 10.1093/jmcb/mjaa071
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in December 2019, causing the illness known as the novel coronavirus disease 2019 (COVID-19). The virus spread rapidly worldwide to become a global public health emergency. As of 15 November 2020, more than 53 million confirmed cases and over one million deaths worldwide have been reported (World Health Organization, 2020). The SARS-CoV-2 genome was sequenced and studies are ongoing to further understand the epidemiology, clinical manifestations, etiological structure, cellular receptor angiotensin II converting enzyme (ACE2), and intracellular replication process of the virus. Currently, thousands of clinical trials related to SARS-CoV-2 are underway (https://clinicaltrials.gov/). However, no vaccines or drugs have yet been approved, until very recently, for direct treatment or prevention of COVID-19 and only supportive treatment has been applied clinically. This review will discuss the possible mechanism of the innate immune response to SARS-CoV-2 infection and provide insight into the development of related therapeutics.